Pricing case: setting a price for cell-derived blood that eases reliance on donors

A biotech company has started selling blood produced from cells instead of collected from donors, which lowers how much the health system depends on donations. As the product manager, how much would you charge for it? Walk through how you would approach the pricing decision, and land on a recommended price. ```hint Bound the price first Before naming a number, work out who actually pays for a unit of blood, then set a lower bound from what the company must recover and an upper bound from what the buyer would otherwise spend. ``` ### Clarifying Questions - Which blood product does it replace (red cells, platelets, plasma or whole blood), and has it been approved and shown to work as well as donated blood? - What does one unit cost to make today, and how many units can the company produce in its first years? - Can it be made in any blood type, including rare ones, and does it keep longer than donated blood? - Which market are we pricing for first, and who pays for blood there: hospitals, insurers, governments or patients? ### What a Strong Answer Covers - The buyer and the payer identified, and how that shapes willingness to pay - A cost floor and a value ceiling, each built from labeled assumptions with correct arithmetic - How value differs across uses or patients, and the pricing strategy chosen, with its rationale - A concrete recommended price with a sanity check and a view of how it should change as production grows - Ethical, reimbursement and donor-supply risks of pricing a life-saving product ### Follow-up Questions - During a severe donor shortage, demand jumps far above what you can make. Do you raise the price, hold it, or ration supply, and how? - How would you test hospitals' willingness to pay before launch? - How would your price change if a second company launched a comparable product two years later?